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We aimed to compare trends in place of cancer death with the growth of palliative care and nursing home services, and investigate
demographic, disease-related and area influences on individual place of death, using registration data for 216404 patients with breast,
lung, colorectal and prostate cancer and aggregate data on services in South East England. Between 1985 and 1994 there was a trend
away from hospital death (67–44%), to home (17–30%) and hospice death (8–20%). After 1995, this partly reversed. By 2002,
hospital death rose to 47%, home death dropped to 23%, hospice death remained stable and nursing home death rose from 3 to 8%.
Numbers of palliative care services increased, but trends for hospice and nursing home deaths most clearly followed the beds
available. Cancer diagnosis and treatment influenced individual place of death, but between 1998 and 2002, age and area of residence
were associated with most variation. Older patients and those living in more deprived areas died more often in hospitals and less
often at home. Despite more palliative care services the proportion of people dying at home has not increased. Variation by age,
deprivation and area of residence is unlikely to reflect patient preference. More active surveillance and planning must support policies
for choice in end of life care.
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Most people say they would prefer to die at home, but in reality
most patients in the UK spend their final days in hospital (WHO,
2004a). Over the last 30 years, hospices, palliative care teams and
units have developed with the aim of improving care towards the
end of life, and allowing people to die where they wish, if this is
possible. Services have initially focused on patients with cancer,
primarily because of the relative ease of predicting the course of
this disease, and a national policy for supportive and palliative
cancer care is now in place (House of Commons Health
Committee, 2004; NICE, 2004a,b). There is, therefore, increasing
interest in Europe about whether data on place of death can be
used as an interim measure of the success of services provided
(WHO, 2004a). Figures for England and Wales revealed a trend
away from death in hospital or nursing homes to hospices between
1985 and 1994, but very little change in home deaths, which
remained around 26%. However, this proportion varied between
regions and was lowest in South East England across all age and
cancer types (Higginson et al, 1998). For common cancers,
individual, disease-related and area of residence factors were
consistently associated with, but not strongly predictive of place
of death. Men, patients aged under 74 years, those with lung
or colorectal cancer or living in more affluent areas were more
likely to die at home than women, patients aged over 75 years,
those with breast cancer or those living in less affluent areas
(Higginson et al, 1998, 1999).
The Thames Cancer Registry covers a population of 14 million
people in South East England, an area with one of the highest
concentrations of hospice and palliative care services in the UK
(Hospice Information, 2006). We used Registry data to describe
trends in place of death for common cancers and compared these
to the growth of palliative care services and nursing homes
between 1985 and 2002. We then investigated the relationship
between demographic, disease-related factors and individual place
of death throughout the period, and the additional influence of
area of residence between 1998 and 2002.
METHODS
In the UK cancer registries record the occurrence of cancer in their
residential populations as well as treatments given in the first 6
months after diagnosis. Information about death is provided by
the National Health Service Central Register through the Office for
National Statistics. Death certificates routinely record place of
death and assign cancer as a main or contributing cause of death in
part I of the certificate.
We extracted data on 216404 residents in South East England
who had been diagnosed with breast, lung, colorectal and prostate
cancer between 1985 and 2002, and who died from their disease
between 1985 and 2002. Cases where the only registration
information was from the death certificate were not included.
From death certificates, we classified death as occurring in NHS
acute hospitals, hospices, long stay hospitals or nursing homes,
private hospitals, at home or as unknown. We could identify
nursing homes by their address, but death certificates do not
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sdistinguish deaths in hospital palliative care units from those in
other wards.
We extracted data on hospice and palliative care services from
Hospice Information directories for 1985–2002 (Hospice Informa-
tion, 2006) and calculated the number of hospice beds, home care
teams, day care services, hospital palliative care or support teams
and hospital support nurses in our area. We summed home care
services regardless of their funding (independent, NHS and
Macmillan Cancer Relief) or base (hospices, NHS hospital or
community), although there was insufficient detail about Marie
Curie home services to include these. We could not deduce team
size or caseload. We also obtained aggregate data on numbers of
beds in registered nursing homes from the Department of Health
where this was available for 1991–2001. We first plotted the
proportion of deaths occurring in each of home, hospital, hospice
and nursing home against the growth of different services over
time. Data on acute and general hospital beds in our area were
available only between 1996 and 2002 and were not plotted.
We then took death in hospice, nursing home, NHS acute
hospital and at home as our four dependent variables and fitted
logistic regression models to identify individual demographic,
disease-related and area of residence factors predicting in turn
each of these outcomes versus the others. Our first analysis for the
entire period 1985–2002 included sex, age at diagnosis, whether
the diagnosis was based on clinical or microscopic evidence,
primary site of cancer and treatment with surgery, radiotherapy,
chemotherapy or hormone therapy. We also adjusted for year of
death and years since diagnosis to examine trends over time. We
grouped age into four bands: o65 years, 65–74 years, 75–84 years
and 85 years plus. Our second analysis explored the additional
influence of area of residence for the years 1998–2002. For this, we
assigned each individual to an electoral ward and a cancer network
using their postcode of residence. We calculated the deprivation
score for each ward using the income domain of the Indices
of Multiple Deprivation (IMD) 2000 for England (Department
of Environment, 2000) and assigned individuals to a quintile of
deprivation ranging from most (1) to least affluent (5) wards.
We present the results of logistic regression analyses as
proportions of deaths occurring in each place for each factor.
Proportions are easier to interpret than odds ratios, and were
derived from a back calculation from the odds ratios obtained
from the logistic regression analyses. We present unadjusted and
adjusted proportions to show the effect of controlling for all other
factors. Our large sample size means that many small differences
reach statistical significance. We draw attention only to those
factors producing at least five percentage points difference – a
difference which we believe a clinical service might be interested to
explore further.
RESULTS
The average age of death for patients in this cohort increased from
71.3 years in 1985 to 72.7 in 2002. The proportion dying at age of
85 years and over increased from 8 to 12% while the proportion
dying between the age of 65 and 74 years dropped from 34 to 28%.
How has place of death changed?
Figure 1 suggests that the period 1985–2002 is best considered in
two phases – before and after 1994. In the first phase, hospital
deaths declined from 67 to 44% – a trend that appeared to be
mirrored by a combined increase in home death from 17 to 30%
and in hospice death from 8 to 20%. In the second phase, however,
the movement away from hospital death appeared to partly
reverse. Between 1995 and 2002 hospital death rose to 47%,
nursing home death to 8%, hospice death remained stable and
home deaths dropped to 23%. In 2002 – the last year of the study –
home death and nursing home death home appear to have
increased slightly and hospital death to have decreased. During
1992 and 1995 there were changes in processing and receipt of our
registry data which may be responsible for the ‘mirroring’ of
trends in hospital and home deaths during this period. This
artefact overlies but does not explain the reversal of overall trends
which is also seen in national data for this period.
Figure 2 shows that during the first phase, while home and
hospice death increased, the provision of home care services and
hospice beds also increased. From 1995 onwards while nursing
home death and hospital death increased, nursing home beds
and, to a lesser degree, the sum of hospital palliative care services
(teams and nurses) also increased. For nursing home deaths,
unlike hospice deaths, there is a lag of several years between the
rise of available beds in these services and deaths within them. The
decline in home death occurring after 1995 did not appear to
follow a substantial drop in the provision of palliative home care
or day care services, which both remained stable, although during
this period the availability of nursing home beds was increasing.
Which individual and disease-related factors affect place
of death?
Table 1 shows unadjusted and adjusted proportions of deaths
in each place for individual demographic and disease-related
factor over the entire study period. Hospital death was more
likely for patients aged over 75, those with lung or breast cancer, a
clinical rather than microscopic diagnosis, and those not receiving
radiotherapy. Home death was more likely for those with
colorectal cancer and those aged less than 75 years. Hospice death
was also more likely for colorectal cancer and for those aged less
than 75 years. Nursing home death increased with older age (4%
for those aged 65–74 years and 12% of those aged over 85 years).
Did place of residence affect place of death between 1998
and 2002?
Our analysis for the most recent years included area of residence as
assessed by cancer network of residence and deprivation of ward
of residence (Table 2). The results for demographic and disease-
related factors were broadly similar to those in Table 1, although
nursing home deaths become more likely for those with breast and
prostate cancer. However, much more striking was the variation by
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Figure 1 Trends for place of death for patients with breast, colorectal,
lung and prostate cancer in South East England 1985–2002. Note: Figure
excludes the proportion dying in private hospitals and patients where place
of death was not known.
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sarea of residence. Concentrating on the nine of 13 cancer networks
that we completely cover, the adjusted proportion of patients dying
in hospital ranged from 39% in Sussex to 60% in West London.
Home deaths ranged from 16% in Surrey, West Sussex and
Hampshire to 27% in South Essex. Hospice death ranged from 10%
in West London to 31% in Surrey, West Sussex and Hampshire.
Nursing home deaths ranged from 4% in North London to 13% in
Sussex. Of London networks, South East London had the lowest
rate of hospital death (49%) and the highest rate of home death
(23%). Patients from more deprived areas died more often in
hospital and less often at home. There was no important
deprivation gradient for nursing home or hospice death.
DISCUSSION
Summary of main findings
This study of 216404 patients diagnosed and dying from four
common cancers in South East England found an initial trend
away from hospital death (67–44%) to home (17–30%) and
hospice death (8–20%) between 1985 and 1994. After 1995 this
trend partly reversed. By 2002, the proportion of hospital deaths
rose to 47%, hospice deaths remained stable, home deaths dropped
to 23% and nursing home deaths rose from 3 to 8%. The number
and range of palliative care services increased but trends for
hospice and nursing home death most clearly followed the
numbers of beds available. Analysis of individual data showed
that throughout the period disease-related factors had a modest
influence on place of death. Patients with colorectal cancer
were more likely to die at home and in hospices while patients
with lung or breast cancer, no microscopic diagnosis and no
radiotherapy were more likely to die in hospitals. However,
between 1998 and 2002, age and place of residence were asso-
ciated with most variation. Older patients were more likely to
die in hospitals and nursing homes and less likely to die at home
or in hospices. Patients from deprived areas were more likely
to die in hospitals and less likely to die at home. There was
significant variation in each place of death by cancer network
of residence.
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Figure 2 Trends in place of death for patients with breast, lung, colorectal and prostate cancer and the growth of services for care towards the end of life
in South East England 1985–2002. Note: Department of Health Data is only available for 1991–2001 and Hospice Information Directories are not available
for 1986 and 1989.
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sTable 1 Associations of individual demographic and disease-related factors with place of death for cancer patients who died 1985–2002 in South East
England
Acute hospital Home Hospice Nursing home
Number % % Adj Number % % Adj Number % % Adj Number % % Adj Total
Age group
o65 28818 47 47 17332 28 28 12032 20 20 956 2 2 61670
65-74 34777 49 47 18104 26 26 13045 18 20 2467 3 4 70665
75-84 33811 52 48 13960 22 23 10566 16 18 4721 7 8 64921
85+ 10512 55 50 3717 19 22 2046 11 12 2375 12 12 19148
Test for w
2 (1 df) 574.1 51.1 1036. 6 410.7 753.7 271.2 4322.2 3206.3
Trend P o0.001 o0.001 o0.001 o0.001 o0.001 o0.001 o0.001 o0.001
Sex
Male 60626 51 51 29552 25 25 19793 17 17 5005 4 4 118630
Female 47292 48 49 23561 24 23 17896 18 19 5514 6 6 97774
Test for w
2 (1 df) 160.5 46.7 19.2 42.8 97.6 92.0 232.3 139.3
Heterogeneity P o0.001 o0.001 o0.001 o0.001 o0.001 o0.001 o0.001 o0.001
Basis of diagnosis
Clinical 29382 57 57 10763 21 21 6697 13 13 3283 6 6 51936
Microscopic 78536 48 52 42350 26 23 30992 19 16 7236 4 5 164468
Test for w
2 (1 df) 1222.9 219.3 536.2 128.9 959.3 212.1 311.8 55.1
Heterogeneity P o0.001 o0.001 o0.001 o0.001 o0.001 o0.001 o0.001 o0.001
Site
Colorectal 23203 46 46 13381 26 26 9873 19 19 2705 5 5 50937
Lung 54794 54 54 24738 24 23 16166 16 16 3575 4 4 102071
Breast 17375 47 56 9140 24 21 6904 18 14 2304 6 5 37340
Prostate 12546 48 52 5854 22 21 4746 18 18 1935 7 6 26056
Test for w
2 (3 df) 1168.1 837.7 147.8 320.6 354.4 294.2 910.8 115.9
Heterogeneity P o0.001 o0.001 o0.001 o0.001 o0.001 o0.001 o0.001 o0.001
Had noninvestigative surgery
No 78702 51 51 36944 24 24 25189 16 16 7527 5 5 153570
Yes 29216 46 54 16169 26 22 12500 20 17 2992 5 5 62834
Test for w
2 (1 df) 402.2 109.0 67.6 61.6 376.8 0.3 1.9 1.1
Heterogeneity P o0.001 o0.001 o0.001 o0.001 o0.001 0.618 0.171 0.298
Had radiotherapy
No 79090 52 52 34962 23 23 24472 16 16 8182 5 5 151223
Yes 28828 44 43 18151 28 27 13217 20 20 2337 4 5 65181
Test for w
2 (1 df) 1183.5 1240.9 548.2 329.8 528.9 425.9 323.6 2.5
Heterogeneity P o0.001 o0.001 o0.001 o0.001 o0.001 o0.001 o0.001 0.117
Had chemotherapy
No 94814 50 50 45221 24 24 31764 17 17 9976 5 5 187856
Yes 13104 46 49 7892 28 25 5925 21 18 543 2 3 28548
Test for w
2 (1 df) 206.7 12.7 170.4 20.9 253.8 10.6 568.8 125.6
Heterogeneity P o0.001 o0.001 o0.001 o0.001 o0.001 0.001 o0.001 o0.001
Had hormone therapy
No 85818 50 50 41640 24 24 29243 17 17 7631 4 4 170033
Yes 22100 48 49 11473 25 25 8446 18 18 2888 6 5 46371
Test for w
2 (1 df) 115.2 23.8 1.3 8.8 26.1 9.1 236.5 46.6
Heterogeneity P o0.001 o0.001 0.263 0.003 o0.001 0.003 o0.001 o0.001
Year of death
1985 3278 67 67 847 17 17 388 8 8 191 4 4 4866
1986 5473 62 64 1792 20 19 996 11 10 328 4 4 8833
1987 5487 57 61 2294 24 22 1183 12 11 330 3 3 9644
1988 5976 54 59 2660 24 22 1592 14 12 396 4 3 10989
1989 6485 53 58 3212 26 24 1718 14 12 425 3 3 12215
1990 6558 52 57 3415 27 25 1926 15 13 420 3 3 12659
1991 6392 50 56 3506 28 26 2074 16 14 453 4 3 12738
Analysis of cancer registration and service data
E Davies et al
596
British Journal of Cancer (2006) 95(5), 593–600 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sTable 1 (Continued)
Acute hospital Home Hospice Nursing home
Number % % Adj Number % % Adj Number % % Adj Number % % Adj Total
1992 6274 50 55 3318 26 24 2296 18 16 440 3 3 12660
1993 6536 45 50 4345 30 28 2834 19 17 507 3 3 14681
1994 5342 44 50 3730 30 28 2505 20 17 339 3 2 12279
1995 6055 47 54 3170 25 22 2242 17 15 398 3 2 12827
1996 4917 46 53 2625 25 22 2135 20 17 583 5 5 10704
1997 5606 47 54 2765 23 21 2188 18 15 631 5 4 11930
1998 6463 48 55 3062 23 20 2709 20 17 927 7 6 13501
1999 6653 48 55 3247 24 21 2675 19 17 920 7 5 13798
2000 6849 49 56 3008 22 20 2685 19 17 1019 7 6 13893
2001 6812 49 55 2892 21 19 2737 20 17 1019 7 6 13919
2002 6762 47 54 3225 23 21 2806 20 17 1193 8 7 14268
Test for w
2 (1 df) 906.0 353.0 68.3 119.2 949.9 672.1 1087.3 648.8
Trend P o0.001 o0.001 o0.001 o0.001 o0.001 o0.001 o0.001 o0.001
Adjusted model includes: age, sex, basis of diagnosis, site, treatment (surgery, radiotherapy, chemotherapy or hormone therapy), year of death and years since diagnosis.
Table 2 Associations of individual demographic, disease-related and area of residence with place of death for patients who died from Breast, lung,
colorectal or prostate cancer between 1998 and 2002 in South East England
Acute hospital Home Hospice Nursing home
Number % % Adj Number % % Adj Number % % Adj Number % % Adj Total
Age group
o65 8756 45 45 5085 26 26 4578 23 23 411 2 2 19521
65-74 10018 48 46 4963 24 24 4454 21 22 1146 5 5 21058
75-84 10790 50 48 4180 20 21 3727 17 19 2263 11 10 21377
85+ 3975 54 50 1206 16 18 853 11 13 1258 17 14 7423
Test for w
2 (1 df) 219.0 55.6 421.17 213.1 553.8 268.8 2016.8 1293.1
Trend P o0.001 o0.001 o0.001 o0.001 o0.001 o0.001 o0.001 o0.001
Sex
Male 18074 49 49 8369 23 23 7068 19 19 2305 6 6 36629
Female 15465 47 47 7065 22 22 6544 20 20 2773 8 10 32750
Test for w
2 (1 df) 31.2 24.0 16.3 10.0 5.2 5.7 119.7 122.8
Heterogeneity P o0.001 o0.001 o0.001 0.002 0.023 0.017 o0.001 o0.001
Basis of diagnosis
Clinical 8462 56 56 2755 18 18 1977 13 13 1472 10 10 15002
Microscopic 25077 46 49 12679 23 21 11635 21 18 3606 7 9 54377
Test for w
2 (1 df) 495.0 192.4 165.9 56.3 493.1 159.9 173.2 6.5
Heterogeneity P o0.001 o0.001 o0.001 o0.001 o0.001 o0.001 o0.001 0.011
Site
Colorectal 7528 45 45 3799 23 23 3564 21 21 1370 8 8 16714
Lung 15992 53 54 6833 23 22 5429 18 18 1460 5 5 30306
Breast 5853 45 51 2821 22 19 2722 21 18 1184 9 10 13026
Prostate 4166 45 44 1981 21 20 1897 20 22 1064 11 12 9333
Test for w
2 (3 df) 421.7 326.2 12.1 50.3 102.9 106.7 565.1 315.6
Heterogeneity P o0.001 o0.001 0.007 o0.001 o0.001 o0.001 o0.001 o0.001
Had noninvestigative surgery
No 24850 50 50 10836 22 22 9110 18 18 3646 7 7 49630
Yes 8689 44 50 4598 23 22 4502 23 20 1432 7 7 19749
Test for w
2 (1 df) 208.3 1.1 17.1 0.1 176.0 12.1 0.2 0.9
Heterogeneity P o0.001 0.300 o0.001 0.792 o0.001 0.001 0.663 0.341
Had radiotherapy
No 25031 51 51 10122 21 21 8981 18 18 3937 8 8 49142
Yes 8508 42 41 5312 26 25 4631 23 23 1141 6 8 20237
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sLimitations of this study
This population-based study used data collected from medical
records and death certificates for routine cancer registration.
Coding officers may have missed some deaths in new nursing
homes and hospices when their addresses were unfamiliar in the
early part of the study period. Lack of information on death
certificate on deaths in hospital palliative care units and lack of
data on hospital beds meant we could not explore these trends and
it is possible that excluding patients for whom we had only death
certificate data from the analysis introduced some bias. Important
information on patient preference for place of death, functional
status, presence of a carer at home, family support, and hospital
and community services received in the weeks before death
(Grundy et al, 2004; Gomes and Higginson, 2006) is not routinely
collected and is therefore missing from the individual analyses.
Comparison to other findings
No other large UK studies have compared overall trends in place of
death with the growth of services that might support patients to die
in different places. However, one study of North West England
between 1993 and 2000 found that proximity to a hospice or
hospital increased the chances of dying there (Gatrell et al, 2003).
Studies in the US have also found that the availability of beds
and physicians affects death in hospital (Fisher et al, 2003a,b).
National bed data available for 1987 to 1994 when hospital deaths
decreased showed a decline of 19% in the numbers of acute and
general hospital beds (Department of Health, 2006). It, therefore,
seems likely that the initial trend for increasing home death was in
part driven by the decreased availability of hospital beds and the
growth of hospice and palliative home care services. However, it is
more difficult to explain the reversal of the trend for home death
Table 2 (Continued)
Acute hospital Home Hospice Nursing home
Number % % Adj Number % % Adj Number % % Adj Number % % Adj Total
Test for w
2 (1 df) 452.2 525.8 263.5 143.1 192.3 162.9 117.8 2.4
Heterogeneity P o0.001 o0.001 o0.001 o0. 001 o0.001 o0.001 o0.001 0.122
Had chemotherapy
No 27748 49 49 11977 21 21 10409 19 19 4764 8 8 56216
Yes 5791 44 47 3457 26 23 3203 24 20 314 2 5 13163
Test for w
2 (1 df) 122.7 25.4 150.9 25.9 227.3 24.1 508.2 97.0
Heterogeneity P o0.001 o0.001 o0.001 o0.001 o0.001 o0.001 o0.001 o0.001
Had hormone therapy
No 27739 50 50 12320 22 22 10839 19 19 3655 7 7 55958
Yes 5800 43 46 3114 23 25 2773 21 20 1423 11 7 13421
Test for w
2 (1 df) 174.6 28.8 8.8 21.9 11.5 2.3 259.4 8.9
Heterogeneity P o0.001 o0.001 0.003 o0.001 0.001 0.130 o0.001 0.003
Network of residence
North East London 3946 56 56 1353 19 19 1346 19 19 347 5 5 7080
North London 3314 54 55 1224 20 19 1173 19 20 261 4 4 6128
South East London 3533 49 49 1697 24 23 1549 22 22 328 5 5 7204
South West London 2899 49 51 1111 19 17 1472 25 27 313 5 5 5886
West London 3988 58 60 1391 20 19 693 10 10 417 6 6 6829
TCR part of Mount Vernon 2459 50 53 1415 29 26 488 10 11 458 9 9 4924
South Essex 2121 52 54 1165 29 27 415 10 11 338 8 8 4067
Kent & Medway 3663 42 42 2139 24 23 2186 25 26 688 8 7 8793
Surrey, West Sussex and Hampshire 2688 43 48 1232 20 16 1771 28 31 349 6 5 6262
Sussex 2642 38 39 1515 22 20 1625 23 25 1046 15 13 7001
TCR part of Central South Coast 327 25 25 249 19 18 367 28 32 150 12 10 1301
TCR part of Mid Anglia 1734 52 53 791 24 22 473 14 15 328 10 9 3360
TCR part of West Anglia 201 41 45 140 28 24 48 10 11 48 10 9 492
Other/NK 24 46 55 12 23 21 6 12 6 7 13 12 52
Test for w
2 (12 df) 1361.2 1219.7 399.9 401.8 1613.5 1687.6 943.1 690.8
Heterogeneity P o0.001 o0.001 o0.001 o0.001 o0.001 o0.001 o0.001 o0.001
IMD
Most affluent 1 5020 42 42 2926 25 25 2458 21 21 896 8 8 11850
2 5965 46 45 3106 24 23 2449 19 21 1125 9 8 13071
3 6754 48 47 3177 23 22 2620 19 22 1099 8 7 13936
4 7692 51 48 3235 21 20 2891 19 24 1123 7 7 15181
Least affluent 5 8105 53 49 2988 19 18 3190 21 25 834 5 7 15330
NK 3 27 23 2 18 17 4 36 72 1 9 5 11
Test for w
2 (1 df) 362.7 92.2 132.4 152.0 0.8 58.9 67.5 4.5
Trend P o0.001 o0.001 o0.001 o0.001 0.387 o0.001 o0.001 0.035
Adjusted model includes: age, sex, basis of diagnosis, site, treatment (surgery, radiotherapy, chemotherapy or hormone therapy), cancer network of residence and deprivation.
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safter 1995 using the routine service data that is available. The
number of home care teams did not decline, hospital palliative care
services were only just beginning to increase and hospital beds did
not increase nationally until 2001. We can speculate that the
decline in home death was due to other changes in care at home
including the ability of families to provide care, the prior move
of some older adults into nursing homes and the move to GP
cooperatives for out of hours care. These factors could all have led
to increased hospital admission and fewer home deaths.
Turning to predictors of individual place of death, our finding
that younger patients, patients with colorectal cancer and those
living in more affluent areas died more often at home is consistent
with (Higginson et al 1998, 1999) analyses of a partial national
registration dataset up until 1994 . However, we found that patients
with breast and lung cancer were more likely to die in hospital and
we were further able to show that hospital death was associated
with lack of microscopic diagnosis, and no radiotherapy treatment.
This suggests the late admission of patients with advanced stage of
disease. Conversely our finding that a microscopically confirmed
diagnosis and radiotherapy treatment were associated with home
and hospice death suggests that some time within ‘the system’ may
allow for referral to supportive services (Burge et al, 2003). A
recent systematic review of factors predicting home death by
Gomes and Higginson (2006) found that the six strongest
predictors were patients’ low functional status, their preferences,
home care and its intensity, living with relatives and extended
family support. Our new finding that cancer network is an
important cause of variation in home death is consistent with this,
and probably represents a combination of difference by area in
access to home care services, and the nearness of relatives and
extended family. It is very unlikely to represent underlying
variation in patients’ preference for place of death or functional
status. Finally our finding that patients from more deprived areas
were equally likely to die in hospices and nursing homes as those
from affluent areas, contradicts the view that the latter may access
these services more often. Inequalities in hospital and home death
do, however, persist.
Implications for practice and policy
Our findings reveal that despite increased investment in and
provision of palliative care services, cancer patients in South East
England remain twice as likely to die in hospital (47%) than at
home (23%). The proportion dying at home is now lower than a
decade ago, lower than elsewhere in the UK, and far lower than
most patients would prefer. Recent national policy has set out the
evidence that coordinated palliative care services can allow more
people to die at home if they wish (NICE, 2004a,b) and advocated
equity of choice in final place of care. This study covers a period
before most recent initiatives (Gold Standards Framework, 2006;
Marie Curie, 2006) but the variation it finds underlines the need
for much more active local surveillance to drive these policies.
It also suggests that opportunities exist to learn from differing
strategies, organisation and practice within cancer networks. For
example, London networks might ask what it is about service
provision in South East London that produces rates of home death
similar to those outside London. Networks outside London might
ask why hospice deaths are sometimes so high and whether
nursing homes are preventing hospital admission and providing
better symptom control. Our data also suggest that a good place for
clinicians in primary care and acute trusts to start identifying
patients in the palliative stage of disease and determining their
preference for avoiding or planning admission would be the
clinical diagnosis of lung or breast cancer in patients living in
deprived areas for whom radiotherapy treatment is not planned.
The effect of any change in practice across a network can be
monitored easily by the routine work of cancer registries.
Further research
We do not yet fully understand why place of death varies across
the UK, how the nexus of factors around the patient operate
together to influence this (Gomes and Higginson, 2006) and why
home deaths have declined and remain so low in South East
England. The imaginative use of available routine data as part of
the development of cancer intelligence could help us see more
clearly what is happening. For example, trends within individual
cancer networks could reveal the influence of different historical
patterns of service provision. Ecological studies could show us
what happens when a new service such as a hospice opens locally.
Mapping rates geographically by primary care trust could show the
influence of services (beds and teams) and workforce (district
nurses (Shipman et al, 2005), Marie Curie nurses and out of hours
care by general practitioners). Studies of how patients move
between different services and the interdependence between
services are also required. Linking hospital episode statistics data
with cancer registration data will, for example, allow us to explore
where patients with different cancers are admitted to hospital
from, how long they stay and where they are discharged to in the
last months of life. The influence that admission has on rate of
death in different trusts or primary care trusts explored in a
similar way to US studies have done (Wennberg et al, 2004).
Qualitative case studies of selected areas could then focus on
explaining how different patterns of care are perpetuated, or how
change has occurred. Finally in the context of an ageing
population, changes in migration and kinship patterns we need
to determine older people’s preference for death in institutions,
ensure that the information we have on what currently occurs is
available and public so that where possible people may make their
own choices in planning care towards the end of life (WHO,
2004b).
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